Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock ¥18.20, price ¥14.52, upside +25.3%, quality 45 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range ¥13.85 – ¥46.74 · fair‑value band ¥12.01 – ¥22.75 · the ¥14.52 price screens below the ¥18.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Wuhan Easy Diagnosis Biomedicine Co Ltd Class A in your weekly email
Every Wednesday you see whether Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China.
Show moreShow less
The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Stock analysis
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) currently trades at ¥14.52, while our model-based Fair Value estimate is ¥18.20, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.
Scenario range: ¥12.01 (bear) to ¥22.75 (bull), the price of ¥14.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A reported revenue of 265M CNY in FY2025 versus 2.8B CNY in FY2021, a compound −44.7%/yr. Reported net income was −16.5M CNY in FY2025.
Key figures
Market cap 3.4B CNY (≈ $507M) Small · P/S ratio 12.4 · EPS (TTM) ¥−0.2300 · Dividend yield 7.9% · Net margin −19.0% · Return on equity −1.8% · Return on assets (EBIT) 21.2% (5-year average) · Operating margin −43.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 25%, 002932 screens cheaper than that median.
Fair Value models
Bear¥12.01Fair Value ¥18.20Bull¥22.75
Price ¥14.52 · Upside +25.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
58.6% (2020) → −40.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Wuhan Easy Diagnosis Biomedicine Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside+25.3% · Top 25%
Profitability
Return on assets−0.3% · Below median
Net margin (12 months)−19.0% · Bottom 25%
Operating margin (12 months)−43.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)2.1% · Below median
Dividend yield (12 months)7.9% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/002932
Frequently asked questions
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of ¥18.20 versus a price of ¥14.52, about +25% upside (undervalued).
What is the fair value of 002932?
Our model-based fair value for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is ¥18.20 (as of Nov 3, 2026), built from audited fundamentals. The current price: ¥14.52.
What is the quality score of 002932?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Our model-based price target is the fair value of ¥18.20 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario ¥12.01, optimistic scenario ¥22.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥18.20, about +25% upside versus a price of ¥14.52 (undervalued). Cautious scenario ¥12.01, optimistic scenario ¥22.75. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A reported trailing-twelve-month revenue of about 267M CNY (latest available figure, as of Nov 3, 2026).
Does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A pay a dividend?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A currently shows a dividend yield of 7.95% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A has a dividend yield of 7.9%.
What is the intrinsic value of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Easy Diagnosis Biomedicine Co Ltd Class A it is ¥18.20 per share (as of Nov 3, 2026), against a price of ¥14.52. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 002932 trades below its calculated fair value: price ¥14.52, fair value ¥18.20, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002932?
No. The price is what the market pays today (¥14.52); the fair value is what the company's own numbers justify (¥18.20). For Wuhan Easy Diagnosis Biomedicine Co Ltd Class A the two are ¥3.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A worth?
The market values Wuhan Easy Diagnosis Biomedicine Co Ltd Class A at about 3.4B CNY (market capitalisation, as of Nov 3, 2026). Per share that is ¥14.52; our models calculate a fair value of ¥18.20 per share.
What do the bullish and bearish scenarios say about 002932?
Our models span a range for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A: cautious scenario ¥12.01, base ¥18.20, optimistic ¥22.75 per share (as of Nov 3, 2026, price ¥14.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Balance-sheet figures for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (as of Nov 3, 2026): return on equity −1.8%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 002932 from its 52-week high?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A trades at ¥14.52, about 29% below its 52-week high of ¥20.47 and 5% above the low of ¥13.85 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥18.20 is for.
Which stocks are comparable to Wuhan Easy Diagnosis Biomedicine Co Ltd Class A?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Easy Diagnosis Biomedicine Co Ltd Class A stock attractive at the current price?
The data as of Nov 3, 2026: price ¥14.52, calculated fair value ¥18.20 (+25%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002932 calculated?
We run Wuhan Easy Diagnosis Biomedicine Co Ltd Class A through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥18.20 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Wuhan Easy Diagnosis Biomedicine Co Ltd Class A currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The closing price on Nov 6, 2026 was ¥14.52. Our model-based fair value is ¥18.20, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Easy Diagnosis Biomedicine Co Ltd Class A right now?
A fairly wide model range (¥12.01 to ¥22.75) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) come from?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A grew +48.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share +47.7 %, EBIT margin +1.4 %, tax rate −0.1 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
How large is the market capitalisation of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The market capitalisation of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 3.4B CNY (≈ $507M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The price-to-sales ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 12.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A are ¥−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The dividend yield of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 7.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The net margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −19.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The return on equity (ROE) of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
On an EBIT basis the return on assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is 21.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
The operating margin of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −43.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Revenue at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is growing +2.1% versus a year earlier (3y avg −70.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)?
Earnings per share at Wuhan Easy Diagnosis Biomedicine Co Ltd Class A are growing −93.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) generate?
The free cash flow of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A is −161M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) hold?
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A holds more cash than debt, 485M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Wuhan Easy Diagnosis Biomedicine Co Ltd Class A in the live analysis
One click puts Wuhan Easy Diagnosis Biomedicine Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026